This defense contractor and automaker are among the most oversold S&P 500 stocks
Take a look at some of the most oversold and overbought stocks in the S&P 500 this week. Source link
Read MoreTake a look at some of the most oversold and overbought stocks in the S&P 500 this week. Source link
Read MoreThe Dow Jones Industrial Average is set to close out a 10-day winning streak on Friday. Source link
Read MorePatients with early Alzheimer's disease could still pay more than $5,000 in out-of-pocket costs for Leqembi even with Medicare coverage.
Read MorePros on CNBC discussed Biogen after the Food and Drug Administration approved its Alzheimer's drug. Source link
Read MoreAnalysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the
Read MoreThese are the stocks posting the largest moves in midday trading. Source link
Read MoreLeqembi is the first Alzheimer's antibody treatment to receive full FDA approval. Source link
Read MoreLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling
Read MoreMedicare has promised to broadly cover Leqembi, which costs $26,500 per year, if the FDA grants full approval of the
Read More